葛兰素史克Exdensur获FDA批准

Core Viewpoint - GSK's stock rose by 1% following the FDA approval of its drug Exdensur (depemokimab) for severe eosinophilic asthma, which can reduce annual acute exacerbation rates by up to 58% compared to placebo [1] Group 1 - GSK's Exdensur received FDA approval as an additional therapy administered twice a year for severe eosinophilic asthma [1] - The SWIFT clinical trial demonstrated that Exdensur can significantly lower the annual acute exacerbation rate by up to 58% when compared to a placebo [1]